|
Eurazeo SE (RF.PA): BCG Matrix [Apr-2026 Updated] |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Eurazeo SE (RF.PA) Bundle
Eurazeo's portfolio is firing on multiple cylinders-Private Debt, Secondaries, Wealth Solutions and Sustainable Infrastructure are rapid-growth engines fueling AUM and deal flow, while Mid-Large Buyouts, recurring fee income and Elevate deliver the steady cash that funds dividends and buybacks; at the same time high-potential Growth, Impact and Venture funds need scale and capital to prove themselves, and legacy Real Estate, older buyouts (notably WorldStrides) and balance-sheet assets are being wound down or divested to free capital-read on to see how these shifts shape risk, returns and strategic allocation.
Eurazeo SE (RF.PA) - BCG Matrix Analysis: Stars
Stars - Private Debt
Private Debt activity leads growth with massive fundraising momentum. Fee Paying Assets Under Management (FPAUM) rose 19% to €7.2 billion as of September 2025. Fundraising for the first nine months of 2025 reached €1.7 billion, including €0.9 billion in Q3 2025 alone. Direct Lending remains a market leader in the European mid‑market, with deployments up 24% year‑on‑year to €2.0 billion over the nine‑month period, illustrating both share gains and rapid portfolio scaling despite macro uncertainty.
The financial metrics for Private Debt (9M 2025):
| Metric | Value |
|---|---|
| FPAUM (Sept 2025) | €7.2 billion |
| Fundraising (9M 2025) | €1.7 billion |
| Fundraising (Q3 2025) | €0.9 billion |
| Deployments (9M 2025) | €2.0 billion |
| YoY FPAUM growth | +19% |
| YoY Deployments growth | +24% |
Key operational and strategic strengths for Private Debt:
- Market leadership in European mid‑market direct lending.
- Diversified deal flow enabling high deployment velocity (€2.0bn in 9M).
- Fundraising momentum provides fee base scalability (FPAUM €7.2bn).
- Resilience to macro uncertainty due to floating‑rate structures and covenant protection.
Stars - Secondaries & Mandates
Secondaries and Mandates strategy captures high market demand for liquidity. This line supported dynamic fundraising in 2025 and materially contributed to €1.4 billion raised in Private Equity over the first nine months. The strategy capitalizes on institutional sellers seeking secondary exits while overall fundraising declined ~10% in the market, enabling Eurazeo to increase relative market share. Deployments remain robust as the Group provides flexible capital solutions via a mid‑market platform.
Secondaries & Mandates key figures (9M 2025):
| Metric | Value |
|---|---|
| Contribution to Private Equity fundraising (9M 2025) | Part of €1.4 billion |
| Private Equity fundraising (9M 2025) | €1.4 billion |
| Market fundraising trend | Global fundraising -10% |
| Relative market share change | Increase vs. market (qualitative) |
| Deployment trend | Robust (mid‑market focus) |
Strategic advantages for Secondaries & Mandates:
- Ability to source liquidity from institutional sellers in stressed markets.
- Mid‑market specialization enables attractive pricing and faster execution.
- Integration with Private Equity origination channels enhances deal flow.
Stars - Wealth Solutions
Wealth Solutions expands rapidly in retail and private client channels. As of September 2025, the segment represents €5.3 billion or 19% of the Group's third‑party Assets Under Management (AUM). Fundraising from private clients grew by 7% over nine months to €0.7 billion, outperforming general market trends. The EPVE 3 evergreen fund surpassed €3.0 billion in AUM, making it one of the largest private market products targeting mass affluent investors in Europe.
Wealth Solutions performance (Sept 2025):
| Metric | Value |
|---|---|
| Wealth Solutions AUM (Sept 2025) | €5.3 billion |
| Share of third‑party AUM | 19% |
| Fundraising from private clients (9M 2025) | €0.7 billion |
| Growth in private client fundraising (9M) | +7% |
| EPVE 3 AUM | >€3.0 billion |
Competitive highlights for Wealth Solutions:
- Strong retail distribution and product (EPVE 3) scale: >€3.0bn AUM.
- Outperformance vs. private client market fundraising trends (+7%).
- Cross‑sell potential with Private Debt and Private Equity offerings for diversified client solutions.
Stars - Sustainable Infrastructure
Sustainable Infrastructure delivers exceptional operational performance and value creation. Portfolio companies showed average revenue growth exceeding 24% as of late 2025. Value creation in sustainable infrastructure assets reached 8% in H1 2025, materially above the broader real assets category. Deployment acceleration continued with eight new impact‑driven transactions announced in Q3 2025, reinforcing the segment's star positioning driven by secular demand for decarbonization and resilient cash flows.
Sustainable Infrastructure metrics (H1 / 9M 2025):
| Metric | Value |
|---|---|
| Average revenue growth (portfolio) | >24% (late 2025) |
| Value creation (H1 2025) | +8% |
| New transactions (Q3 2025) | 8 impact‑driven deals |
| Deployment acceleration | Ongoing (number of deployments increased vs. prior period) |
Core strategic attributes for Sustainable Infrastructure:
- High organic growth in portfolio revenues (>24%).
- Strong absolute and relative value creation (+8% H1 2025).
- Alignment with ESG and energy transition demand supporting premium valuations and fundraising.
Eurazeo SE (RF.PA) - BCG Matrix Analysis: Cash Cows
Cash Cows - Mid-Large Buyout (MLBO) remains the primary engine for management fees, anchoring EURAZEO's fee base. MLBO manages a significant portion of the €19.0 billion Private Equity FPAUM (up 4% year-on-year). The Capital EC V program successfully closed at €3.0 billion in 2025, exceeding its initial target and securing long-term fee visibility. Management fees from third-party private market activities reached €166 million over the first nine months of 2025, supported by a high average fee rate of 108 basis points, which underpins predictable cash generation from recurring management fees.
| Metric | Value | Period/Notes |
|---|---|---|
| Private Equity FPAUM | €19.0 bn | +4% YoY (2025) |
| Capital EC V close | €3.0 bn | Closed 2025, above target |
| Third‑party private market management fees | €166 m | 9 months 2025, avg fee 108 bps |
Asset Management Fee-Related Earnings (FRE) provide stable, recurring cash flows and high margin contribution. The FRE margin remained resilient at approximately 34.8% through 2025, reflecting disciplined cost management and operating leverage in fee businesses. Total management fees reached €316 million for the first nine months of 2025, an underlying increase of 2% excluding catch-up effects, driving predictable cash available for shareholder returns. This fee stability underpinned the Group's capital allocation decisions: a 10% dividend increase to €2.65 per share and a €400 million share buyback program.
| FRE Metric | Value | Period/Notes |
|---|---|---|
| FRE margin | 34.8% | 2025 |
| Total management fees | €316 m | 9 months 2025, +2% underlying |
| Dividend per share | €2.65 | +10% vs prior year |
| Share buyback | €400 m | Announced 2025 |
Small-Medium Buyout (Elevate) generates consistent realizations and performance fees, contributing to cash flow and incentive compensation potential. Portfolio companies in this segment reported revenue growth of 6% and EBITDA growth of 17% in H1 2025, driving value crystallization. The Group executed several landmark exits in Q3 2025, contributing to total realizations of €2.2 billion over nine months. These realizations are approaching distribution points that should increase performance fees toward the Group's target of performance fees representing ~10% of revenue.
- Portfolio revenue growth (Elevate): +6% (H1 2025)
- Portfolio EBITDA growth (Elevate): +17% (H1 2025)
- Total realizations (all buyout segments): €2.2 bn (9 months 2025)
- Performance fee revenue target: approx. 10% of total revenue (strategic aim)
iM Global Partner (iMGP) contributes steady third-party management fee growth and diversification outside direct private equity. Management fees from iMGP rose by 6% to €44 million in H1 2025. As of September 2025, iMGP's own AUM stood at $46.2 billion, up 2% year-on-year, providing a diversified, low‑capex revenue stream with high recurrence and limited parent capital commitments. This stable contribution reduces operating leverage risk and supports consolidated cash cow characteristics.
| iMGP Metric | Value | Period/Notes |
|---|---|---|
| Management fees (iMGP) | €44 m | H1 2025, +6% YoY |
| iMGP AUM | $46.2 bn | As of Sep 2025, +2% YoY |
| CapEx requirement for parent | Minimal | Stable recurring income |
Eurazeo SE (RF.PA) - BCG Matrix Analysis: Question Marks
The Dogs quadrant-low relative market share in low-growth markets-at Eurazeo primarily captures units that currently occupy niche positions or face market headwinds despite strategic importance: Growth Equity IV (EGF IV), Eurazeo Planetary Boundaries Fund (EPBF), and Venture Capital/Biotech strategies. These units exhibit mixed performance: selective revenue acceleration in newer vintages, significant capital deployment needs, high innovation potential but valuation pressure, and limited contribution to total AUM relative to the Group's scale.
The following table summarizes key metrics for each unit as of 2025 to frame their Dogs-position attributes (low growth, low relative share):
| Business Unit | First Closing / Target | 2025 Revenue Growth (latest vintages) | Fair Value Movement (2025) | Deployment / Capital Committed | Transactions / Activity | Contribution to Group AUM (€37.4bn) |
|---|---|---|---|---|---|---|
| Growth Equity IV (EGF IV) | €650m first close; target €1.0bn | 37%-40% for most recent vintage companies | Portfolio fair value nearly stable; subject to market adjustments | High deployment: €3.9bn across growth sectors (Group-wide figure) | Active deployment in select markets; fundraising ongoing | Minor relative share versus core LBO and Private Equity segments |
| Eurazeo Planetary Boundaries Fund (EPBF) | €300m+ first close; target €750m by late 2025 | Project-level revenue momentum; early-stage impact scaling | Early-stage valuation; subject to regulatory and market sensitivity | Rapid deployment momentum across 13 transactions H1 2025 | 13 transactions in H1 2025; high deployment cadence | Represents a small fraction of €37.4bn total AUM (single-digit %) |
| Venture Capital & Biotech (incl. Kurma Biofund IV) | Fundraising underway for Kurma Biofund IV | Venture portfolio revenue +4% in 2025 | Additional fair value adjustments: -€0.3bn across Growth & Venture | Continued follow-on capital required to retain portfolio positions | Ongoing fundraising; selective exits constrained by market | Limited relative market share vs. global venture platforms |
Key characteristics justifying Dogs classification:
- Limited relative market share within large private markets dominated by larger global players.
- Low or unstable near-term growth for the consolidated unit-level fair value, despite pockets of high vintage revenue growth.
- High capital intensity and deployment requirements to pursue leadership (e.g., €3.9bn deployment context) with uncertain incremental returns.
- Valuation headwinds and negative fair value adjustments (notably -€0.3bn impacting Growth & Venture) reducing short-term contribution to Group NAV.
- Strategic importance for diversification and innovation, but currently small contribution to total AUM (EPBF <1%-a few % of €37.4bn).
Short- and medium-term performance drivers to monitor:
- Fundraising success: closing EGF IV at €1.0bn target and EPBF at €750m will determine scale economics and fee income.
- Realized exits and mark-to-market adjustments in Growth and Venture affecting fair value and carried interest potential.
- Deployment efficiency: converting €3.9bn deployment capacity into value-creating market positions.
- Regulatory and impact-market dynamics shaping EPBF's growth potential and fundraising appetite.
- Competition from larger global venture platforms influencing relative market share in biotech and tech venture deals.
Quantitative indicators to track quarterly:
- Fund closings and committed capital (EGF IV target vs. current €650m; EPBF target €750m vs. €300m+ closed).
- Portfolio revenue growth rates by vintage (EGF IV recent vintages: 37%-40%; Venture overall: +4% in 2025).
- Fair value movements and impairment/write-downs (current combined adjustment -€0.3bn across Growth & Venture).
- Number and size of transactions (EPBF: 13 transactions H1 2025).
- Relative share of Group AUM (track EPBF and Venture share vs. €37.4bn total AUM).
Eurazeo SE (RF.PA) - BCG Matrix Analysis: Dogs
Question Marks - Dogs
The Real Estate (Real Assets) segment registered notable valuation pressure in a soft market environment: the fair value of the Real Assets portfolio, excluding infrastructure, declined by 6% in H1 2025 amid high interest rates and market uncertainty. Fundraising for Real Assets was nearly stagnant, falling 93% to €6 million in H1 2025. Operationally, hotel activities produced a modest +3% revenue uptick, which was insufficient to offset the broader property value contraction and limited capital-raising capacity.
| Metric | Value / Change | Period |
|---|---|---|
| Real Assets fair value (ex. infrastructure) | -6% | H1 2025 vs. prior |
| Real Assets fundraising | €6 million (-93%) | H1 2025 vs. prior |
| Hotel operations revenue | +3% | H1 2025 vs. prior |
| Buyout legacy impairments | -€0.4 billion | Late 2024 - Early 2025 |
| Balance sheet AUM | €9.4 billion (-9%) | 12 months to Sep 2025 |
| Management fees on balance sheet | €58 million (-2%) | Trailing period |
| Balance-sheet realizations (portfolio) | 14% of portfolio | Ongoing |
Legacy Buyout assets are a persistent drag: impairments of older vintages produced a -€0.4 billion fair value adjustment in late 2024 and early 2025. These assets generally show lower growth profiles than newer vintages and are prioritized for accelerated rotation. The Group has realized balance-sheet positions equivalent to 14% of the portfolio as part of the deleveraging and reallocation strategy.
WorldStrides is a concentrated underperformer within Buyout: it required a material value adjustment at end-2024 and recorded continued sales declines that depressed 2025 results. Excluding WorldStrides, Buyout revenues expanded by 6%, underscoring the asset-specific nature of the underperformance and supporting the case for exit or restructuring of legacy travel-related holdings.
- Accelerated divestment: targeted sales of legacy Buyout positions to improve portfolio quality and realize fair value.
- Reallocation of capital: shift from balance-sheet AUM to share buybacks and third-party fund growth.
- Operational remediation: potential restructuring or targeted exits for underperforming assets such as WorldStrides.
- Fundraising focus: prioritize third-party fundraising to reduce exposure to low-growth, capital-intensive balance-sheet holdings.
Balance-sheet contraction is deliberate: Balance sheet AUM decreased by 9% to €9.4 billion (12 months to September 2025) as management repositions toward a third-party model. Management fees derived from balance-sheet assets totaled €58 million, down 2% after disposals and reduced commitments. This segment continues to consume capital that the Group is redirecting toward buybacks and external fund development.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.